Difference between revisions of "Treatment"
m (→What is currently known?) |
m (→Topic 1) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
=What is currently known?= | =What is currently known?= | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | = | + | =Chloroquine= |
==Observations== | ==Observations== | ||
| + | * Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On the basis of the weak evidence available to date, treatment guidelines have already incorporated the usage of chloroquine/hydroxychloroquine for certain patients with COVID-19. <Ref name="CEBM2503Chlor">Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19. CEBM Oxford. March 25, 2020</ref> | ||
| + | * Further research should address the optimal dose and duration of treatment, and explore side effects and long-term outcomes. <Ref name="CEBM2503Chlor"/> | ||
| + | * There is a higher risk of side effects in the presence of renal and liver impairment, and there have been isolated reports of COVID-19 disease-causing renal and hepatic injury.<Ref name="CEBM2503Chlor"/> | ||
| + | * Over twenty in vivo clinical trials have already been registered to test the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.<Ref name="CEBM2503Chlor"/> | ||
| + | * Contraindications for the use of these drugs must be checked for each individual before treatment. Empirical evidence suggests that hydroxychloroquine has a better safety profile, and it might, therefore, be preferable to focus research efforts on this less toxic metabolite.<Ref name="CEBM2503Chlor"/> | ||
| + | |||
==Analysis and interpretation== | ==Analysis and interpretation== | ||
| + | |||
==Consequences for action== | ==Consequences for action== | ||
| − | + | * [Hydroxy]chloroquine: needs more research | |
=References= | =References= | ||
Latest revision as of 09:02, 29 March 2020
This page collects observations, interpretations, and consequences for action about theTreatmentof SARS-CoV2 in general. Please observe the structure of the page, when you add your content. Please use references where possible. Remember to find the relevant page. For example, if your observation is about transmission routes, please use that page, instead of posting your content here.
Contents
What is currently known?
Chloroquine
Observations
- Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On the basis of the weak evidence available to date, treatment guidelines have already incorporated the usage of chloroquine/hydroxychloroquine for certain patients with COVID-19. [1]
- Further research should address the optimal dose and duration of treatment, and explore side effects and long-term outcomes. [1]
- There is a higher risk of side effects in the presence of renal and liver impairment, and there have been isolated reports of COVID-19 disease-causing renal and hepatic injury.[1]
- Over twenty in vivo clinical trials have already been registered to test the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.[1]
- Contraindications for the use of these drugs must be checked for each individual before treatment. Empirical evidence suggests that hydroxychloroquine has a better safety profile, and it might, therefore, be preferable to focus research efforts on this less toxic metabolite.[1]
Analysis and interpretation
Consequences for action
- [Hydroxy]chloroquine: needs more research
